MedPath

AGENNIX

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

17

Active:0
Completed:7

Trial Phases

3 Phases

Phase 1:7
Phase 2:6
Phase 3:4

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (17 trials with phase data)• Click on a phase to view related trials

Phase 1
7 (41.2%)
Phase 2
6 (35.3%)
Phase 3
4 (23.5%)

Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis

Phase 2
Suspended
Conditions
Severe Sepsis
Interventions
First Posted Date
2011-01-11
Last Posted Date
2012-02-03
Lead Sponsor
Agennix
Target Recruit Count
1280
Registration Number
NCT01273779
Locations
🇺🇸

University of Alabama - Birmingham, Birmingham, Alabama, United States

🇺🇸

Providence Hospital, Mobile, Alabama, United States

🇺🇸

Maricopa Medical Center, Maricopa, Arizona, United States

and more 96 locations

Safety and Tolerability of RGB-286638 in Patients With Selected, Relapsed or Refractory Hematological Malignancies

Phase 1
Withdrawn
Conditions
Hematological Malignancies
First Posted Date
2010-07-23
Last Posted Date
2012-08-02
Lead Sponsor
Agennix
Registration Number
NCT01168882

Study of Talactoferrin Oral Solution for Nosocomial Infection in Preterm Infants

Phase 1
Conditions
Nosocomial Infections
Interventions
Drug: Placebo
First Posted Date
2009-03-03
Last Posted Date
2012-03-15
Lead Sponsor
Agennix
Target Recruit Count
120
Registration Number
NCT00854633
Locations
🇺🇸

Childrens Hospital of Los Angeles, Los Angeles, California, United States

🇺🇸

Kosair Children's Hospital, Louisville, Kentucky, United States

🇺🇸

University of Louisville Hospital, Louisville, Kentucky, United States

and more 1 locations

Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer

Phase 3
Completed
Conditions
Non Small Cell Lung Cancer
Interventions
Drug: Placebo
First Posted Date
2008-06-30
Last Posted Date
2012-08-21
Lead Sponsor
Agennix
Target Recruit Count
742
Registration Number
NCT00707304
Locations
🇺🇸

Desert Oasis Cancer Center, Casa Grande, Arizona, United States

🇺🇸

Arizona Oncology Associates, Tucson, Arizona, United States

🇺🇸

University of Colorado Hospital, Aurora, Colorado, United States

and more 183 locations

Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer

Phase 3
Conditions
Non Small Cell Lung Cancer
Interventions
Drug: Placebo
First Posted Date
2008-06-30
Last Posted Date
2012-03-15
Lead Sponsor
Agennix
Target Recruit Count
1100
Registration Number
NCT00706862
Locations
🇺🇸

City of Hope, Duarte, California, United States

🇺🇸

Rush University Medical Center, Chicago, Illinois, United States

🇺🇸

Montefiore Medical Center, Bronx, New York, United States

and more 3 locations
  • Prev
  • 1
  • 2
  • 3
  • 4
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.